The Lysine Demethylase KDM4C Is an Oncogenic Driver and Regulates ERK Activity in KRAS-Mutant Pancreatic Ductal Adenocarcinoma.

Saved in:
Bibliographic Details
Title: The Lysine Demethylase KDM4C Is an Oncogenic Driver and Regulates ERK Activity in KRAS-Mutant Pancreatic Ductal Adenocarcinoma.
Authors: Shaheen MT; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Sheikh Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, Texas., Dhebat S; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Sheikh Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, Texas., Rajapakshe KI; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Sheikh Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, Texas., Ghosh B; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Sheikh Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, Texas., Chellakkan Selvanesan B; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Sheikh Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, Texas., Ansari SS; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Sheikh Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, Texas., Haymaker CL; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Sadeghian D; Department of Pathology and Immunology, Baylor College of Medicine, Houston, Texas., Wang H; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Anatomical Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Li CF; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Ying H; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Maitra A; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Sheikh Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Source: Cancer research communications [Cancer Res Commun] 2026 Jan 01; Vol. 6 (1), pp. 245-259.
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9918281580506676 Publication Model: Print Cited Medium: Internet ISSN: 2767-9764 (Electronic) Linking ISSN: 27679764 NLM ISO Abbreviation: Cancer Res Commun Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2767-9764
DOI:10.1158/2767-9764.CRC-25-0278